Key Takeaways Myriad Genetics' GeneSight test showed superiority over treatment-as-usual in major depression.A meta-analysis of six trials with 3,532 patients highlighted MYGN's GeneSight test's clinical benefits.Patients using MYGN's GeneSight were 41% more likely to achieve remission and 30% more likely to respond.Myriad Genetics, Inc. (MYGN) recently published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test o ...

New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across SpecialtiesSECAUCUS, N.J., Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced an advanced pharmacogenomic (PGx) laboratory test service designed to help providers understand the patient's individual genetic response to select drug therapies. This innovative offering aims to help providers determine appropriate me ...

Results published in the Journal of Clinical PsychopharmacologySALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when GeneSight® Psychotropic test results were available to treating clinicians, there were significant i ...

Core Insights - New pharmacogenomic data on the impact of the UNC13A genotype on treatment response in ALS patients treated with NurOwn® will be presented at the ISCT 2025 Annual Meeting [1][2] - The findings are significant as they may help predict treatment responses based on genetic factors, advancing personalized medicine for ALS [2][3] Company Overview - BrainStorm Cell Therapeutics Inc. is a leading developer of autologous adult stem cell therapies for neurodegenerative diseases, with its proprietary NurOwn® platform utilizing mesenchymal stem cells to produce neurotrophic factor-secreting cells [4][5] - NurOwn® has received Orphan Drug designation from both the FDA and EMA, and a Phase 3 trial in ALS has been completed, with a confirmatory Phase 3b trial set to launch under a Special Protocol Assessment agreement with the FDA [5][6] Clinical Development - The upcoming Phase 3b trial aims to build on existing clinical data and demonstrate NurOwn's potential in early ALS, with positive communication ongoing with the FDA [3][5] - The recent findings provide insights into treatment effects in patient subpopulations and represent a first-of-its-kind pharmacogenomic analysis in ALS, focusing on how genetic differences affect therapy response [3][6] Presentation Details - The oral presentation titled "Debamestrocel Effect on Clinical and Biomarker Endpoints by UNC13A Genotype in Phase 3 ALS Trial" will take place on May 8, 2025, at the ISCT meeting in New Orleans [3]